> Details

Teyssonneau, Diego; Dariane, Charles; Barret, Eric; Beauval, Jean-Baptiste; Brureau, Laurent; Fiard, Gaëlle; Fromont, Gaëlle; Créhange, Gilles; Gauthé, Mathieu; Ruffion, Alain; Renard-Penna, Raphaële; Mathieu, Romain; Sargos, Paul; Rouprêt, Morgan; Ploussard, Guillaume; Roubaud, Guilhem

PARP inhibitors in prostate cancers, is it time for combinations?

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: PARP inhibitors in prostate cancers, is it time for combinations?
  • Contributor: Teyssonneau, Diego; Dariane, Charles; Barret, Eric; Beauval, Jean-Baptiste; Brureau, Laurent; Fiard, Gaëlle; Fromont, Gaëlle; Créhange, Gilles; Gauthé, Mathieu; Ruffion, Alain; Renard-Penna, Raphaële; Mathieu, Romain; Sargos, Paul; Rouprêt, Morgan; Ploussard, Guillaume; Roubaud, Guilhem
  • Published: SAGE Publications, 2024
  • Published in: Therapeutic Advances in Medical Oncology, 16 (2024)
  • Language: English
  • DOI: 10.1177/17588359241242959
  • ISSN: 1758-8359
  • Origination:
  • Footnote:
  • Description: Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular BRCA2. More recently, it has been hypothesized that new hormonal therapies (NHTs) and PARP inhibitors (PARPi) could have synergistic actions and act independently of HRR deficiency. This review proposes to discuss the advantages and disadvantages of PARPi used as monotherapy or in combination with NHTs and whether there is a need for molecular selection.
  • Access State: Open Access